345658-02-8

Basic information

• Product Name: Cyclopentanamine, 2,2-dimethyl-
• Synonyms: 2,2-Dimethyl-cyclopentylamine;Cyclopentanamine, 2,2-dimethyl-;2,2-DiMethyl CyclopentanaMine
• CAS NO: 345658-02-8
• Molecular Formula: C₇H₁₅N
• Molecular Weight: 113.2007
• Product Categories: Amines;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals;Amines, Intermediates, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 345658-02-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 133.7±8.0 °C(Predicted)
• Appearance: /
• Density: 0.840±0.06 g/cm3(Predicted)
• PKA: 10.85±0.40(Predicted)
• CAS DataBase Reference: Cyclopentanamine, 2,2-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopentanamine, 2,2-dimethyl-(345658-02-8)
• EPA Substance Registry System: Cyclopentanamine, 2,2-dimethyl-(345658-02-8)

Safety Data

• Hazardous Substances Data: 345658-02-8(Hazardous Substances Data)

Usage

Description

Cyclopentanamine, 2,2-dimethylis an organic compound with the molecular formula C7H15N. It is a derivative of cyclopentanamine, featuring two methyl groups attached to the second carbon atom. This structural characteristic endows it with unique chemical properties and reactivity, making it a valuable building block in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
Cyclopentanamine, 2,2-dimethylis used as a synthetic intermediate for the development of 4-substituted benzamides. These benzamides are recognized for their potent, selective, and orally bioavailable properties as IKs blockers. IKs blockers are crucial in the treatment of cardiac arrhythmias, particularly atrial fibrillation, by selectively targeting and blocking the slowly activating delayed rectifier potassium current (IKs) channels in the heart. The use of Cyclopentanamine, 2,2-dimethylin this context aids in the creation of novel and effective therapeutic options for managing cardiac conditions.

Upstream product

• 4541-32-6 2,2-dimethylcyclopentanone 

Relevant articles and documents

Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists

CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists. Extensive SAR studies, wherein molecules' property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compound 68 with a desirable PFI. Compound 68 demonstrated good in vitro pharmacology with excellent selectivity over CXCR1 and other chemokine receptors. Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compound in both species. In addition, the compound demonstrated dose-dependent efficacy in the in vivo pharmacology neutrophil infiltration "air pouch" model in rodents after oral administration. Further, compound 68 is a CNS penetrant molecule with high unbound fraction in brain tissue.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable IKs blockers

Multiple delayed rectifier potassium currents, including IKs, are responsible for the repolarization and termination of the cardiac action potential, and blockers of these currents may be useful as antiarrhythmic agents. Modification of compound 5 produced 19(S) that is the most potent IKs blocker reported to date with > 5000-fold selectivity over other cardiac ion channels. Further modification produced 24A with 23% oral bioavailability.